Pipeline

Wholly Owned

Contact us to learn more about out-licensing our assets.

logo x37
Disease Area (Target)
Discovery
Optimization
IND Enabling
Phase 1
Immunology (TYK2)
Immunology (RIPK2)
Oncology (Undisclosed)
Oncology (Undisclosed)
Immunology (Undisclosed)
Immunology (Undisclosed)

Learn more about our portfolio, pipeline, and career opportunities.

Contact Us